December 21, 2016 09:00 ET

AXIM Biotech's Innovative Delivery System Garners Media Attention --

REDONDO BEACH, CA--(Marketwired - Dec 21, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing recent national media coverage of AXIM Biotechnologies' (OTCQB: AXIM) innovative cannabinoid delivery systems -- including its cannabinoid-containing chewing gum. After launching CanChew™ as an over-the-counter CBD nutraceutical, the company is advancing MedChew RX -- which contains both CBD and THC -- through clinical trials for pain and muscle spasms in multiple sclerosis patients along with other programs.

In a recent article, Fox Business News highlighted the company's cannabinoid-containing chewing gum and outlined its significant potential within the market. CEO Dr. George Anastassov told the network that he anticipates MedChew RX to complete Phase III clinical trials by the third or fourth quarter of 2017 and be fully registered by 2018, while noting that the company's proprietary extraction methods set it apart from the competition.

The company has also been featured in a growing number of financial publications. For example, Keith Speights covered the stock on the Motley Fool in November as one of the five best biotech stocks of the year. Mr. Speights noted the company's 2,000% share price increase and its upcoming launch of several new products in 2017, including its CannQuit smoking cessation chewing gum, and clinical milestones for MedChew RX.

Forbes contributor Debra Borchardt further discussed the company's human clinical trials targeting CBG for psoriasis in May 2016. In the article, Ms. Borchardt discusses the company's clinical trials that will be conducted at The Maurits Clinical in The Hague under the direction of Dr. Marcus Meinardi. The dermatology study will use "stem cell cannabinoid" cannabigerol (CBG) as a chief component -- a lesser known but powerful antagonist.

In terms of clinical programs, the company plans to enter Phase IIA studies for its MedChew RX for multiple sclerosis patients next year. The company also plans to soon launch clinical studies for its dermatology, IBS, and glaucoma products. These programs could generate near-term catalysts in the form of clinical results, while successful outcomes could lead to commercialization partnerships that could involve milestone payments.

Follow the link to read the full article:


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information